The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.